Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections

Highlights • Fosfomycin (FOS) was non-inferior to ertapenem (ETP) for treatment of extended-spectrum β-lactamase urinary tract infections (ESBL UTIs). • The matched subanalyses supported FOS non-inferiority over ETP. • FOS should be considered a carbapenem-sparing alternative in ESBL UTIs.

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2016-07, Vol.48 (1), p.56-60
Main Authors: Veve, Michael P, Wagner, Jamie L, Kenney, Rachel M, Grunwald, Jenny L, Davis, Susan L
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Antimicrobial stewardship
beta-Lactamases - secretion
beta-Lactams - therapeutic use
Enterobacteriaceae - classification
Enterobacteriaceae - enzymology
Enterobacteriaceae Infections - drug therapy
Enterobacteriaceae Infections - microbiology
Ertapenem
ESBL
Extended-spectrum β-lactamase
Female
Fosfomycin
Fosfomycin - therapeutic use
Humans
Infectious Disease
Male
Middle Aged
Outpatients
Patient Readmission
Retrospective Studies
Treatment Outcome
Urinary Tract Infections - drug therapy
UTI
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Fosfomycin (FOS) was non-inferior to ertapenem (ETP) for treatment of extended-spectrum β-lactamase urinary tract infections (ESBL UTIs). • The matched subanalyses supported FOS non-inferiority over ETP. • FOS should be considered a carbapenem-sparing alternative in ESBL UTIs.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2016.04.014